DE2912105C2 - Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittel - Google Patents
Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittelInfo
- Publication number
- DE2912105C2 DE2912105C2 DE2912105A DE2912105A DE2912105C2 DE 2912105 C2 DE2912105 C2 DE 2912105C2 DE 2912105 A DE2912105 A DE 2912105A DE 2912105 A DE2912105 A DE 2912105A DE 2912105 C2 DE2912105 C2 DE 2912105C2
- Authority
- DE
- Germany
- Prior art keywords
- crystals
- group
- propoxy
- colorless
- dihydrocarbostyril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 45
- 238000004519 manufacturing process Methods 0.000 title description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 454
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 221
- -1 3,4,5-trimethoxy benzoyloxy group Chemical group 0.000 claims description 141
- 150000001875 compounds Chemical class 0.000 claims description 101
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 69
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 7
- 241001233037 catfish Species 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 241000272517 Anseriformes Species 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 239000013078 crystal Substances 0.000 description 455
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 198
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 148
- 238000002844 melting Methods 0.000 description 85
- 230000008018 melting Effects 0.000 description 85
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 72
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 71
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 67
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 56
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 53
- 125000004193 piperazinyl group Chemical group 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 238000001914 filtration Methods 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000000354 decomposition reaction Methods 0.000 description 30
- 238000004821 distillation Methods 0.000 description 27
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 27
- 238000010992 reflux Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 238000001953 recrystallisation Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 17
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 16
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 235000011121 sodium hydroxide Nutrition 0.000 description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 150000007514 bases Chemical class 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 10
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 10
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 10
- 229940086542 triethylamine Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 9
- 239000012442 inert solvent Substances 0.000 description 9
- 150000004682 monohydrates Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 235000009518 sodium iodide Nutrition 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 239000008096 xylene Substances 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 4
- IEMFRASHQUBMQP-UHFFFAOYSA-N 6-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 IEMFRASHQUBMQP-UHFFFAOYSA-N 0.000 description 4
- QBLRMOJWUWFFOU-UHFFFAOYSA-N 6-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 QBLRMOJWUWFFOU-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 150000004683 dihydrates Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- AWISGSJZNFRYNE-UHFFFAOYSA-N ethanol;dihydrochloride Chemical compound Cl.Cl.CCO AWISGSJZNFRYNE-UHFFFAOYSA-N 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CIZJPPDMQJRHQT-UHFFFAOYSA-N 1-benzyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(CC=3C=CC=CC=3)C(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 CIZJPPDMQJRHQT-UHFFFAOYSA-N 0.000 description 3
- ZUGRYLJRHKHZLR-UHFFFAOYSA-N 1h-quinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2NC(=O)C=CC2=C1 ZUGRYLJRHKHZLR-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- RRBYJBJQLCHSIT-UHFFFAOYSA-N 7-[3-(4-benzylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1OCCCN(CC1)CCN1CC1=CC=CC=C1 RRBYJBJQLCHSIT-UHFFFAOYSA-N 0.000 description 3
- MWBDVKHHXQNPOO-UHFFFAOYSA-N 8-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=12NC(=O)CCC2=CC=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 MWBDVKHHXQNPOO-UHFFFAOYSA-N 0.000 description 3
- LTUWYBFZTRXBPB-UHFFFAOYSA-N 8-bromo-6-chloro-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound ClC1=CC=2CCC(=O)NC=2C(Br)=C1OCCCN(CC1)CCN1C1=CC=CC=C1 LTUWYBFZTRXBPB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YZGRCIMYJXKBAW-UHFFFAOYSA-N 1-hexyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(CCCCCC)C(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 YZGRCIMYJXKBAW-UHFFFAOYSA-N 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- ZDMQTPPAJCUOQG-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC(=O)CCC2=C1 ZDMQTPPAJCUOQG-UHFFFAOYSA-N 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- HKTZKESTBBPIET-UHFFFAOYSA-N 5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=CC=2NC(=O)CCC=2C=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 HKTZKESTBBPIET-UHFFFAOYSA-N 0.000 description 2
- BKLZJEDYTSEFQS-UHFFFAOYSA-N 5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one;hydrochloride Chemical compound Cl.C=1C=CC=2NC(=O)CCC=2C=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 BKLZJEDYTSEFQS-UHFFFAOYSA-N 0.000 description 2
- FYLSBGSTHGTSMF-UHFFFAOYSA-N 5-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2OCCCN(CC1)CCN1C1=CC=CC=C1 FYLSBGSTHGTSMF-UHFFFAOYSA-N 0.000 description 2
- RTDDASPUDRTKQK-UHFFFAOYSA-N 6,8-dichloro-5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound ClC=1C=C(Cl)C=2NC(=O)CCC=2C=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 RTDDASPUDRTKQK-UHFFFAOYSA-N 0.000 description 2
- KOWNZCLKAYVANJ-UHFFFAOYSA-N 6-[3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 KOWNZCLKAYVANJ-UHFFFAOYSA-N 0.000 description 2
- MODSSQOFCATBKT-UHFFFAOYSA-N 6-chloro-7-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C(=CC=3CCC(=O)NC=3C=2)Cl)CC1 MODSSQOFCATBKT-UHFFFAOYSA-N 0.000 description 2
- LGPLIDOVQNKWEM-UHFFFAOYSA-N 7-[2-methyl-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2CCC(=O)NC2=CC=1OCC(C)CN(CC1)CCN1C1=CC=CC=C1 LGPLIDOVQNKWEM-UHFFFAOYSA-N 0.000 description 2
- GTTWBLBQRGTZTI-UHFFFAOYSA-N 7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 GTTWBLBQRGTZTI-UHFFFAOYSA-N 0.000 description 2
- UHLXVWIMGXDONK-UHFFFAOYSA-N 7-[3-[4-(2-ethoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound CCOC1=CC=CC=C1N1CCN(CCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 UHLXVWIMGXDONK-UHFFFAOYSA-N 0.000 description 2
- AYOYRQBAZIBAOY-UHFFFAOYSA-N 7-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-1h-quinolin-2-one Chemical compound COC1=CC=CC=C1N1CCN(CCCOC=2C=C3NC(=O)C=CC3=CC=2)CC1 AYOYRQBAZIBAOY-UHFFFAOYSA-N 0.000 description 2
- SSOZDVWIIKSYKX-UHFFFAOYSA-N 7-[3-[4-(4-chlorophenyl)piperazin-1-yl]-2-hydroxypropoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2CCC(=O)NC2=CC=1OCC(O)CN(CC1)CCN1C1=CC=C(Cl)C=C1 SSOZDVWIIKSYKX-UHFFFAOYSA-N 0.000 description 2
- OMIHGPLIXGGMJB-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2OC2=C1 OMIHGPLIXGGMJB-UHFFFAOYSA-N 0.000 description 2
- VFCYYYIWSCXZOH-UHFFFAOYSA-N 8-chloro-5-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one Chemical compound ClC=1C=CC(=C2CCC(NC=12)=O)OCCCN1CCN(CC1)C1=CC=CC=C1 VFCYYYIWSCXZOH-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KVVSCMOUFCNCGX-UHFFFAOYSA-N cardol Chemical compound CCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 KVVSCMOUFCNCGX-UHFFFAOYSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229920001519 homopolymer Chemical class 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 description 1
- VLRRPMQPJDBERH-UHFFFAOYSA-N 1-(3-methylbutyl)-5-(oxiran-2-ylmethoxy)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(CCC(C)C)C(=O)CCC2=C1OCC1CO1 VLRRPMQPJDBERH-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- VZOFCATXWWIFHP-UHFFFAOYSA-N 1-benzyl-5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one Chemical compound C1CN(C=2C=CC=CC=2)CCN1CC(O)COC(C=1CCC2=O)=CC=CC=1N2CC1=CC=CC=C1 VZOFCATXWWIFHP-UHFFFAOYSA-N 0.000 description 1
- KQZMDCXAQGAVDB-UHFFFAOYSA-N 1-benzyl-5-[3-(4-benzylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one Chemical compound C(C1=CC=CC=C1)N1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)CC1=CC=CC=C1 KQZMDCXAQGAVDB-UHFFFAOYSA-N 0.000 description 1
- OAAAIKKLZCJWOR-UHFFFAOYSA-N 1-ethyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=C2N(CC)C(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 OAAAIKKLZCJWOR-UHFFFAOYSA-N 0.000 description 1
- MDJOKTXXPXPSFJ-UHFFFAOYSA-N 1-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(C)C(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 MDJOKTXXPXPSFJ-UHFFFAOYSA-N 0.000 description 1
- RVARRQDAYWHEDF-UHFFFAOYSA-N 1-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]quinolin-2-one Chemical compound C=1C=C2C=CC(=O)N(C)C2=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 RVARRQDAYWHEDF-UHFFFAOYSA-N 0.000 description 1
- HTRHNJKNDSYOKP-UHFFFAOYSA-N 1h-quinolin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC(=O)C=CC2=C1 HTRHNJKNDSYOKP-UHFFFAOYSA-N 0.000 description 1
- ONGYDIMWAUSQQR-UHFFFAOYSA-N 1h-quinolin-2-one;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1=CC=C2NC(=O)C=CC2=C1 ONGYDIMWAUSQQR-UHFFFAOYSA-N 0.000 description 1
- ZVIYOMSQJXDIGZ-UHFFFAOYSA-N 1h-quinolin-2-one;hydrate;hydrochloride Chemical compound O.Cl.C1=CC=C2NC(=O)C=CC2=C1 ZVIYOMSQJXDIGZ-UHFFFAOYSA-N 0.000 description 1
- FUMPJRHQRZIMBV-UHFFFAOYSA-N 2-[4-[3-[(2-oxo-3,4-dihydro-1h-quinolin-5-yl)oxy]propyl]piperazin-1-yl]ethyl acetate Chemical compound C1CN(CCOC(=O)C)CCN1CCCOC1=CC=CC2=C1CCC(=O)N2 FUMPJRHQRZIMBV-UHFFFAOYSA-N 0.000 description 1
- ZLWNJNCMMZHAKK-UHFFFAOYSA-N 2-[4-[3-[(2-oxo-3,4-dihydro-1h-quinolin-7-yl)oxy]propyl]piperazin-1-yl]ethyl acetate Chemical compound C1CN(CCOC(=O)C)CCN1CCCOC1=CC=C(CCC(=O)N2)C2=C1 ZLWNJNCMMZHAKK-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- YNZNESKPSHZISM-UHFFFAOYSA-N 3-propoxy-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(OCCC)=CC2=C1 YNZNESKPSHZISM-UHFFFAOYSA-N 0.000 description 1
- ADGOXYJGBCFSCG-UHFFFAOYSA-N 4-[3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C12=CC=CC=C2NC(=O)C=C1OCCCN(CC1)CCN1C1=CC=CC=C1 ADGOXYJGBCFSCG-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QYYOIMPOXWFIGS-UHFFFAOYSA-N 4-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C=1C=C2C(C)=CC(=O)NC2=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 QYYOIMPOXWFIGS-UHFFFAOYSA-N 0.000 description 1
- NEAQKRDPVKKECM-UHFFFAOYSA-N 4-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one dihydrochloride Chemical compound Cl.Cl.CC1CC(=O)Nc2cc(OCCCN3CCN(CC3)c3ccccc3)ccc12 NEAQKRDPVKKECM-UHFFFAOYSA-N 0.000 description 1
- DBNTWLFHZZMEBN-UHFFFAOYSA-N 4-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2C(C)CC(=O)NC2=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 DBNTWLFHZZMEBN-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- XVZLCNDAYXZALB-UHFFFAOYSA-N 4-phenyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C12=CC=C(OCCCN3CCN(CC3)C=3C=CC=CC=3)C=C2NC(=O)C=C1C1=CC=CC=C1 XVZLCNDAYXZALB-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- LSPQUUCPTFYZFH-UHFFFAOYSA-N 5-(3-chloro-2-methylpropoxy)-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(CCl)C LSPQUUCPTFYZFH-UHFFFAOYSA-N 0.000 description 1
- CJRUUYXOJCDRQS-UHFFFAOYSA-N 5-[2-[4-(4-methylphenyl)piperazin-1-yl]ethoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(C)=CC=C1N1CCN(CCOC=2C=3CCC(=O)NC=3C=CC=2)CC1 CJRUUYXOJCDRQS-UHFFFAOYSA-N 0.000 description 1
- CMHFEMADALKZNR-UHFFFAOYSA-N 5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-1-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(C)C(=O)CCC2=C1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 CMHFEMADALKZNR-UHFFFAOYSA-N 0.000 description 1
- KOXGUMRCRGCEHF-UHFFFAOYSA-N 5-[3-(4-acetylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CN(C(=O)C)CCN1CCCOC1=CC=CC2=C1CCC(=O)N2 KOXGUMRCRGCEHF-UHFFFAOYSA-N 0.000 description 1
- SZFDGAFMPHFFDD-UHFFFAOYSA-N 5-[3-(4-benzoylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CN(CCCOC=2C=3CCC(=O)NC=3C=CC=2)CCN1C(=O)C1=CC=CC=C1 SZFDGAFMPHFFDD-UHFFFAOYSA-N 0.000 description 1
- WWOBBQZLFKCLBO-UHFFFAOYSA-N 5-[3-(4-benzoylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one;hydrochloride Chemical compound Cl.C1CN(CCCOC=2C=3CCC(=O)NC=3C=CC=2)CCN1C(=O)C1=CC=CC=C1 WWOBBQZLFKCLBO-UHFFFAOYSA-N 0.000 description 1
- LYNBULMOSZKORR-UHFFFAOYSA-N 5-[3-(4-cyclohexylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2OCCCN(CC1)CCN1C1CCCCC1 LYNBULMOSZKORR-UHFFFAOYSA-N 0.000 description 1
- GTADJKVNUKGLND-UHFFFAOYSA-N 5-[3-(4-phenyl-1,4-diazepan-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2OCCCN(CC1)CCCN1C1=CC=CC=C1 GTADJKVNUKGLND-UHFFFAOYSA-N 0.000 description 1
- MDUYTTKHWFIMJV-UHFFFAOYSA-N 5-[3-[4-(2-ethoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound CCOC1=CC=CC=C1N1CCN(CCCOC=2C=3CCC(=O)NC=3C=CC=2)CC1 MDUYTTKHWFIMJV-UHFFFAOYSA-N 0.000 description 1
- KSSAUGUQWMMCHT-UHFFFAOYSA-N 5-[3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound FC1=CC=CC=C1N1CCN(CCCOC=2C=3CCC(=O)NC=3C=CC=2)CC1 KSSAUGUQWMMCHT-UHFFFAOYSA-N 0.000 description 1
- GCQQBMYYDUGOAM-UHFFFAOYSA-N 5-[5-[4-(2-methoxyphenyl)piperazin-1-yl]pentoxy]-3,4-dihydro-1H-quinolin-2-one Chemical compound COC1=C(C=CC=C1)N1CCN(CC1)CCCCCOC1=C2CCC(NC2=CC=C1)=O GCQQBMYYDUGOAM-UHFFFAOYSA-N 0.000 description 1
- ASJBMPKNQXCABP-UHFFFAOYSA-N 6,8-dichloro-5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one;hydrochloride Chemical compound Cl.ClC=1C=C(Cl)C=2NC(=O)CCC=2C=1OCC(O)CN(CC1)CCN1C1=CC=CC=C1 ASJBMPKNQXCABP-UHFFFAOYSA-N 0.000 description 1
- BPSCGYGLXVBSGI-UHFFFAOYSA-N 6-(3-chloropropoxy)-4-methyl-1h-quinolin-2-one Chemical compound C1=C(OCCCCl)C=C2C(C)=CC(=O)NC2=C1 BPSCGYGLXVBSGI-UHFFFAOYSA-N 0.000 description 1
- ROIXGKBSXQUWFY-UHFFFAOYSA-N 6-[3-(dimethylamino)propoxy]-4-phenyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C12=CC(OCCCN(C)C)=CC=C2NC(=O)CC1C1=CC=CC=C1 ROIXGKBSXQUWFY-UHFFFAOYSA-N 0.000 description 1
- IVLDYECWPDUNFM-UHFFFAOYSA-N 6-[4-(4-phenylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one Chemical compound C1(=CC=CC=C1)N1CCN(CC1)CCCCOC=1C=C2CCC(NC2=CC=1)=O IVLDYECWPDUNFM-UHFFFAOYSA-N 0.000 description 1
- IJURCEDAUNYUNJ-UHFFFAOYSA-N 6-bromo-7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound BrC1=CC=2CCC(=O)NC=2C=C1OCCCN(CC1)CCN1C1=CC=CC=C1 IJURCEDAUNYUNJ-UHFFFAOYSA-N 0.000 description 1
- SLNNIFNQIHQNHU-UHFFFAOYSA-N 6-chloro-7-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one Chemical compound ClC=1C=C2CCC(NC2=CC=1OCC(CN1CCN(CC1)C1=CC=CC=C1)O)=O SLNNIFNQIHQNHU-UHFFFAOYSA-N 0.000 description 1
- NQCVIXJSFZMILF-UHFFFAOYSA-N 7-(3-chloropropoxy)-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(OCCCCl)=CC=C21 NQCVIXJSFZMILF-UHFFFAOYSA-N 0.000 description 1
- KHFYKOXCAGSRRU-UHFFFAOYSA-N 7-[3-(4-cyclohexylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1CCCCC1 KHFYKOXCAGSRRU-UHFFFAOYSA-N 0.000 description 1
- WQKHYFRVMZFJIF-UHFFFAOYSA-N 7-[3-(4-phenyl-1,4-diazepan-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1OCCCN(CC1)CCCN1C1=CC=CC=C1 WQKHYFRVMZFJIF-UHFFFAOYSA-N 0.000 description 1
- SPULWLDIJURFIR-UHFFFAOYSA-N 7-[3-(4-phenylpiperazin-1-yl)propoxy]-1h-quinolin-2-one Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 SPULWLDIJURFIR-UHFFFAOYSA-N 0.000 description 1
- PIIMLTKXVGVIQX-UHFFFAOYSA-N 7-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-quinolin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=C2NC(=O)CCC2=CC=C1OCCCN(CC1)CCN1C1=CC=CC=C1 PIIMLTKXVGVIQX-UHFFFAOYSA-N 0.000 description 1
- SKHLKHODMJVMFM-UHFFFAOYSA-N 7-[3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound FC1=CC=CC=C1N1CCN(CCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 SKHLKHODMJVMFM-UHFFFAOYSA-N 0.000 description 1
- ZCJUWHTZIRCAJR-UHFFFAOYSA-N 7-[3-[4-(3,4,5-trimethoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound COC1=C(OC)C(OC)=CC(N2CCN(CCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1 ZCJUWHTZIRCAJR-UHFFFAOYSA-N 0.000 description 1
- JUHGJQHJMUJTGH-UHFFFAOYSA-N 7-[3-[4-(3,4,5-trimethoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C(OC)=CC(N2CCN(CCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1 JUHGJQHJMUJTGH-UHFFFAOYSA-N 0.000 description 1
- ZKAYRIOGIKAXJC-UHFFFAOYSA-N 7-[3-[4-(3-chlorophenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound ClC1=CC=CC(N2CCN(CCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1 ZKAYRIOGIKAXJC-UHFFFAOYSA-N 0.000 description 1
- JVNMPWKMTPMFSP-UHFFFAOYSA-N 7-[3-[4-(3-fluorophenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound FC1=CC=CC(N2CCN(CCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1 JVNMPWKMTPMFSP-UHFFFAOYSA-N 0.000 description 1
- AQCPVZHEXDLGLX-UHFFFAOYSA-N 7-[3-[4-(4-chlorophenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 AQCPVZHEXDLGLX-UHFFFAOYSA-N 0.000 description 1
- BIQLBWJBHMYYCG-UHFFFAOYSA-N 7-[3-[4-(4-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 BIQLBWJBHMYYCG-UHFFFAOYSA-N 0.000 description 1
- MLUSPPKOSUCWLV-UHFFFAOYSA-N 7-[3-[4-(4-methylphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(C)=CC=C1N1CCN(CCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 MLUSPPKOSUCWLV-UHFFFAOYSA-N 0.000 description 1
- USIMZAIRLDAIQJ-UHFFFAOYSA-N 7-[4-(4-phenylpiperazin-1-yl)butoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC=C1 USIMZAIRLDAIQJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- STOPIRBWVSZODR-UHFFFAOYSA-N 8-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-1h-quinolin-2-one Chemical compound COC1=CC=CC=C1N1CCN(CCCOC=2C=3NC(=O)C=CC=3C=CC=2)CC1 STOPIRBWVSZODR-UHFFFAOYSA-N 0.000 description 1
- CUIKMKFHNHPLPY-UHFFFAOYSA-N 8-bromo-5-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C(Br)=CC=C2O CUIKMKFHNHPLPY-UHFFFAOYSA-N 0.000 description 1
- JQIYRNJVUSDOHE-UHFFFAOYSA-N 8-bromo-6-chloro-7-(3-chloropropoxy)-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=C(Br)C(OCCCCl)=C(Cl)C=C21 JQIYRNJVUSDOHE-UHFFFAOYSA-N 0.000 description 1
- MOLBSSKZUWCGDL-UHFFFAOYSA-N 8-chloro-5-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one Chemical compound ClC=1C=CC(=C2CCC(NC=12)=O)OCC(CN1CCN(CC1)C1=CC=CC=C1)O MOLBSSKZUWCGDL-UHFFFAOYSA-N 0.000 description 1
- KVUNUEJUGQVORJ-UHFFFAOYSA-N 8-chloro-5-[3-[4-(4-chlorophenyl)piperazin-1-yl]-2-hydroxypropoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C(Cl)C=2NC(=O)CCC=2C=1OCC(O)CN(CC1)CCN1C1=CC=C(Cl)C=C1 KVUNUEJUGQVORJ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FNZFNHARJBFHTE-UHFFFAOYSA-N C(C)(C)N1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 Chemical compound C(C)(C)N1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 FNZFNHARJBFHTE-UHFFFAOYSA-N 0.000 description 1
- KCARTBPVBLTZJF-UHFFFAOYSA-N C(C)N1C(=O)CCC2=CC(=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 Chemical compound C(C)N1C(=O)CCC2=CC(=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 KCARTBPVBLTZJF-UHFFFAOYSA-N 0.000 description 1
- UTRMKMFSMLXFDR-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C(=O)CCC2=C(C(=CC=C12)Cl)OCCCN1CCN(CCC1)CC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)N1C(=O)CCC2=C(C(=CC=C12)Cl)OCCCN1CCN(CCC1)CC1=CC=CC=C1 UTRMKMFSMLXFDR-UHFFFAOYSA-N 0.000 description 1
- KTSDCDIZTBMRAB-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C(=O)CCC2=CC(=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)N1C(=O)CCC2=CC(=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 KTSDCDIZTBMRAB-UHFFFAOYSA-N 0.000 description 1
- PQQMSNYFNVIAPI-UHFFFAOYSA-N C(CC)N1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 Chemical compound C(CC)N1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 PQQMSNYFNVIAPI-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- RSTMBRSFFCRNSC-UHFFFAOYSA-N Cl.Cl.CN1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 Chemical compound Cl.Cl.CN1C(=O)CCC2=C(C=CC=C12)OCCCN1CCN(CC1)C1=CC=CC=C1 RSTMBRSFFCRNSC-UHFFFAOYSA-N 0.000 description 1
- HTAGKFDBPGLJMQ-UHFFFAOYSA-N Cl.OC(COC=1C=C2CCC(NC2=CC1)=O)CN1CCN(CC1)C1=CC=C(C=C1)Cl Chemical compound Cl.OC(COC=1C=C2CCC(NC2=CC1)=O)CN1CCN(CC1)C1=CC=C(C=C1)Cl HTAGKFDBPGLJMQ-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- APGWPUQMIBRIQN-UHFFFAOYSA-N O=C1NC2=CC(OCCCN(CC3)CCN3C(C=C3)=CC=C3F)=CC=C2CC1 Chemical compound O=C1NC2=CC(OCCCN(CC3)CCN3C(C=C3)=CC=C3F)=CC=C2CC1 APGWPUQMIBRIQN-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- ZJQHXCFDPZNALX-UHFFFAOYSA-N [1-[(2-oxo-3,4-dihydro-1h-quinolin-7-yl)oxy]-3-(4-phenylpiperazin-1-yl)propan-2-yl] acetate Chemical compound C=1C=C2CCC(=O)NC2=CC=1OCC(OC(=O)C)CN(CC1)CCN1C1=CC=CC=C1 ZJQHXCFDPZNALX-UHFFFAOYSA-N 0.000 description 1
- ZNMSDGGOBMBEPZ-UHFFFAOYSA-N [ClH]1C=CCC1 Chemical compound [ClH]1C=CCC1 ZNMSDGGOBMBEPZ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UFMJCOLGRWKUKO-UHFFFAOYSA-N cardol diene Natural products CCCC=CCC=CCCCCCCCC1=CC(O)=CC(O)=C1 UFMJCOLGRWKUKO-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical group CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 239000012495 reaction gas Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000004623 sleep-prolonging effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3778378A JPS54130587A (en) | 1978-03-30 | 1978-03-30 | Carbostyryl derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2912105A1 DE2912105A1 (de) | 1979-10-11 |
| DE2912105C2 true DE2912105C2 (de) | 1985-08-29 |
Family
ID=12507080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2912105A Expired DE2912105C2 (de) | 1978-03-30 | 1979-03-27 | Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittel |
| DE2953723A Expired DE2953723C2 (de) | 1978-03-30 | 1979-03-27 | Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2953723A Expired DE2953723C2 (de) | 1978-03-30 | 1979-03-27 | Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittel |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US4734416A (cg-RX-API-DMAC10.html) |
| JP (1) | JPS54130587A (cg-RX-API-DMAC10.html) |
| AT (1) | AT376432B (cg-RX-API-DMAC10.html) |
| AU (1) | AU515531B2 (cg-RX-API-DMAC10.html) |
| BE (1) | BE875174A (cg-RX-API-DMAC10.html) |
| CA (1) | CA1117110A (cg-RX-API-DMAC10.html) |
| CH (2) | CH641455A5 (cg-RX-API-DMAC10.html) |
| DE (2) | DE2912105C2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK158225C (cg-RX-API-DMAC10.html) |
| ES (4) | ES479134A1 (cg-RX-API-DMAC10.html) |
| FI (1) | FI70704C (cg-RX-API-DMAC10.html) |
| FR (1) | FR2421174A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB2017701B (cg-RX-API-DMAC10.html) |
| IT (1) | IT1119284B (cg-RX-API-DMAC10.html) |
| MX (1) | MX5862E (cg-RX-API-DMAC10.html) |
| NL (1) | NL183189C (cg-RX-API-DMAC10.html) |
| NO (1) | NO151321C (cg-RX-API-DMAC10.html) |
| PT (1) | PT69422A (cg-RX-API-DMAC10.html) |
| SE (1) | SE434945B (cg-RX-API-DMAC10.html) |
| SU (2) | SU1140687A3 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA791516B (cg-RX-API-DMAC10.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7910589B2 (en) | 2001-09-25 | 2011-03-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8030312B2 (en) | 2001-01-29 | 2011-10-04 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2827566A1 (de) * | 1978-06-23 | 1980-01-10 | Boehringer Mannheim Gmbh | 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung |
| DE3034237A1 (de) * | 1979-09-18 | 1981-04-16 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel |
| PH17194A (en) | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
| JPS57193461A (en) * | 1981-05-22 | 1982-11-27 | Otsuka Pharmaceut Co Ltd | Benzazepine derivative |
| DE3442570A1 (de) * | 1984-11-22 | 1986-05-22 | Hoechst Ag, 6230 Frankfurt | Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere |
| JPS6129331A (ja) * | 1985-03-13 | 1986-02-10 | アラ−ガン・ハンフリ− | 検眼装置 |
| DK588486A (da) * | 1985-12-09 | 1987-06-10 | Otsuka Pharma Co Ltd | Anvendelse af en forbindelse til behandling af hypoxi |
| KR940000785B1 (ko) * | 1986-04-02 | 1994-01-31 | 오오쓰까세이야꾸 가부시끼가이샤 | 카르보스티릴 유도체 및 그의 염의 제조 방법 |
| DK167187A (da) * | 1986-04-02 | 1987-10-03 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse |
| JPH0696555B2 (ja) * | 1986-07-31 | 1994-11-30 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| US4886809A (en) * | 1986-07-31 | 1989-12-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
| US4803203A (en) * | 1986-11-05 | 1989-02-07 | Warner-Lambert Company | Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| JPS63141967A (ja) * | 1986-11-21 | 1988-06-14 | エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド | 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール |
| FR2637591B1 (fr) * | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2900130B2 (ja) * | 1995-03-16 | 1999-06-02 | 大塚製薬株式会社 | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| PE20030445A1 (es) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| AU2003291757A1 (en) * | 2002-11-08 | 2004-06-03 | Bristol-Myers Squibb Company | Formulations of low solubility bioactive agents and processes for making the same |
| SI1480953T2 (sl) * | 2003-01-09 | 2010-12-31 | Otsuka Pharma Co Ltd | Postopek za pripravo aripiprazola |
| WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| EA200600071A1 (ru) * | 2003-06-20 | 2006-08-25 | Арена Фармасьютикалз, Инк. | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором |
| US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| US20050032781A1 (en) * | 2003-08-06 | 2005-02-10 | Elliot Ehrich | Methods for administering active agents to CYP 2D6 sensitive patients |
| PL1675573T4 (pl) | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
| GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| US7714129B2 (en) * | 2003-12-16 | 2010-05-11 | Teva Pharmaceutical Industries Ltd. | Methods of preparing anhydrous aripiprazole form II |
| JP5546717B2 (ja) * | 2003-12-16 | 2014-07-09 | テバ ファーマシューティカル インダストリーズ リミティド | アリピプラゾール結晶質形態を調製する方法 |
| MXPA06008828A (es) * | 2004-02-05 | 2007-04-25 | Teva Pharma | Proceso para preparar aripiprazol. |
| US7507823B2 (en) * | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
| CA2565996A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| CN101111481A (zh) * | 2004-11-18 | 2008-01-23 | 斯索恩有限公司 | 制备结晶阿立哌唑的方法 |
| CN101087760B (zh) * | 2004-11-18 | 2011-09-28 | 斯索恩有限公司 | 结晶的阿立哌唑溶剂化物 |
| EP1844792A4 (en) * | 2004-12-14 | 2008-05-21 | Shionogi & Co | THERAPEUTIC AGENT AGAINST OBSTIPATION |
| EP2093217B1 (en) * | 2005-01-27 | 2014-03-12 | Sandoz AG | Process for preparing Form X of aripiprazole |
| EP1686126A1 (en) * | 2005-01-27 | 2006-08-02 | Sandoz AG | Salts of aripiprazole |
| ES2526415T3 (es) * | 2005-03-17 | 2015-01-12 | Synthon B.V. | Comprimidos farmacéuticos de aripiprazol cristalino de tipo II |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| CA2605447A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
| JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
| BRPI0608185A2 (pt) * | 2005-12-22 | 2009-11-17 | Teva Pharma | processo para redução do tamanho de partìcula de aripiprazol |
| WO2007092779A2 (en) * | 2006-02-03 | 2007-08-16 | Dr. Reddy's Laboratories Ltd. | Aripiprazole co-crystals |
| US20060223820A1 (en) * | 2006-03-21 | 2006-10-05 | Chemagis Ltd. | Crystalline aripiprazole salts and processes for preparation and purification thereof |
| EP1880714A1 (en) * | 2006-07-20 | 2008-01-23 | Helm AG | Amorphous Aripiprazole and Process for the Preparation thereof |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| WO2008047340A1 (en) * | 2006-10-19 | 2008-04-24 | Mor Research Applications Ltd. | Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
| WO2008051541A2 (en) * | 2006-10-24 | 2008-05-02 | Cambrex Charles City, Inc. | Process for preparing anhydrous aripirazole type i |
| EP1930396B1 (de) * | 2006-12-04 | 2011-07-06 | Merck Patent GmbH | Furochromanderivate |
| MX2009012506A (es) * | 2007-05-21 | 2009-12-09 | Reviva Pharmaceuticals Inc | Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. |
| NO2170279T3 (cg-RX-API-DMAC10.html) * | 2007-07-31 | 2018-05-26 | ||
| ES2353444T3 (es) | 2008-01-23 | 2011-03-02 | Helm Ag | Aripiprazol amorfo y procedimiento para su preparación. |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| SG195568A1 (en) * | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| EP2321011A1 (en) * | 2008-06-25 | 2011-05-18 | Pfizer Inc. | Diaryl compounds and uses thereof |
| HRP20171415T4 (hr) | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
| JPWO2011030575A1 (ja) | 2009-09-11 | 2013-02-04 | 大塚製薬株式会社 | 慢性疼痛治療剤 |
| WO2011030213A1 (en) | 2009-09-14 | 2011-03-17 | Jubilant Organosys Limited | Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| WO2012068161A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| AU2012231160B2 (en) | 2011-03-18 | 2017-04-06 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| WO2012131451A1 (en) | 2011-03-30 | 2012-10-04 | Jubilant Life Sciences Limited | Process for producing aripiprazole in anhydrous type i crystals |
| TW201309651A (zh) | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| ES2764383T3 (es) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de glicerol |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| AU2013259551B2 (en) * | 2012-05-09 | 2017-11-02 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
| CN104822660A (zh) * | 2012-08-21 | 2015-08-05 | 詹森药业有限公司 | 阿立哌唑半抗原及其在免疫测定中的应用 |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| KR20160139704A (ko) | 2015-05-28 | 2016-12-07 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법 |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| IL319072A (en) | 2022-08-19 | 2025-04-01 | Agenebio Inc | History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment |
| ES2963237A1 (es) * | 2022-08-25 | 2024-03-25 | Consejo Superior Investigacion | Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA801037A (en) * | 1968-12-10 | Regnier Gilbert | Procede de preparation de nouveaux derives du piperazino-phenylethanol | |
| GB1021522A (en) * | 1963-05-10 | 1966-03-02 | Ici Ltd | 2-quinolone derivatives |
| GB1075156A (en) * | 1963-08-27 | 1967-07-12 | Luso Farmaco Inst | Substituted piperazines |
| NL131192C (cg-RX-API-DMAC10.html) * | 1965-06-16 | |||
| US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
| US3706749A (en) * | 1967-03-30 | 1972-12-19 | Mcneilab Inc | N-acyl carbostyrils |
| US3703522A (en) * | 1967-03-30 | 1972-11-21 | Mcneilab Inc | Carbostyril derivatives |
| US3511841A (en) * | 1967-05-29 | 1970-05-12 | Sterling Drug Inc | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines |
| US3635976A (en) * | 1967-12-20 | 1972-01-18 | Pennwalt Corp | 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof |
| CH514611A (de) * | 1968-07-05 | 1971-10-31 | Cassella Farbwerke Mainkur Ag | Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins |
| DE1795362A1 (de) * | 1968-09-19 | 1972-01-05 | Boehringer Mannheim Gmbh | Basische AEther und Verfahren zur Herstellung derselben |
| DE2123923A1 (de) * | 1971-05-14 | 1972-11-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung |
| BE884459Q (fr) * | 1971-05-14 | 1981-01-26 | Boehringer Mannheim Gmbh | Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation |
| DE2335432A1 (de) * | 1973-07-12 | 1975-01-30 | Boehringer Mannheim Gmbh | 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung |
| JPS48103590A (cg-RX-API-DMAC10.html) * | 1972-04-13 | 1973-12-25 | ||
| US3910924A (en) * | 1972-04-13 | 1975-10-07 | Otsuka Pharma Co Ltd | 3,4-Dihydrocarbostyril derivatives and a process for preparing the same |
| US4256890A (en) * | 1972-09-14 | 1981-03-17 | Otsukapharmaceutical Co., Ltd. | 3,4-Dihydrocarbostyril derivatives and process for producing the same |
| NL7314812A (cg-RX-API-DMAC10.html) * | 1972-11-02 | 1974-05-06 | ||
| DE2334009A1 (de) * | 1973-07-04 | 1975-01-23 | Boehringer Mannheim Gmbh | Purin-derivate sowie verfahren zu ihrer herstellung |
| US4026895A (en) * | 1973-09-08 | 1977-05-31 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
| US4083853A (en) * | 1973-09-08 | 1978-04-11 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
| US3981864A (en) * | 1973-09-08 | 1976-09-21 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
| GB1451900A (en) * | 1973-10-30 | 1976-10-06 | Sandoz Ltd | Quinolin-2-1h-ones |
| JPS5089376A (cg-RX-API-DMAC10.html) * | 1973-12-19 | 1975-07-17 | ||
| US4032528A (en) * | 1974-03-25 | 1977-06-28 | Sandoz, Inc. | 1,4-substituted-quinolin-2(1h)-ones as cns agents |
| US3983121A (en) * | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| US3940397A (en) * | 1974-11-13 | 1976-02-24 | E. R. Squibb & Sons, Inc. | 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones |
| DE2631317A1 (de) * | 1975-07-23 | 1977-02-17 | Sandoz Ag | Organische verbindungen, ihre verwendung und herstellung |
| US3994900A (en) * | 1976-01-23 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones |
| ES456325A1 (es) * | 1976-02-27 | 1978-05-01 | Sandoz Ag | Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico. |
| CH619453A5 (cg-RX-API-DMAC10.html) * | 1976-03-17 | 1980-09-30 | Otsuka Pharma Co Ltd | |
| US4210753A (en) * | 1976-03-17 | 1980-07-01 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds |
| DE2719562C2 (de) * | 1976-05-08 | 1986-05-07 | Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo | 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten |
| US4110449A (en) * | 1977-05-23 | 1978-08-29 | E. R. Squibb & Sons, Inc. | 2-substituted benzisothiazol-3-ones |
| US4166116A (en) * | 1977-11-11 | 1979-08-28 | Canadian Patents And Development Limited | Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions |
| EP0005828B1 (de) * | 1978-06-06 | 1981-03-11 | Hoechst Aktiengesellschaft | Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung |
| DE2827566A1 (de) * | 1978-06-23 | 1980-01-10 | Boehringer Mannheim Gmbh | 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung |
-
1978
- 1978-03-30 JP JP3778378A patent/JPS54130587A/ja active Granted
-
1979
- 1979-03-27 DE DE2912105A patent/DE2912105C2/de not_active Expired
- 1979-03-27 CA CA000324227A patent/CA1117110A/en not_active Expired
- 1979-03-27 DE DE2953723A patent/DE2953723C2/de not_active Expired
- 1979-03-28 US US06/024,602 patent/US4734416A/en not_active Expired - Lifetime
- 1979-03-28 AU AU45480/79A patent/AU515531B2/en not_active Expired
- 1979-03-28 FI FI791034A patent/FI70704C/fi not_active IP Right Cessation
- 1979-03-29 SE SE7902794A patent/SE434945B/sv not_active IP Right Cessation
- 1979-03-29 CH CH295379A patent/CH641455A5/de not_active IP Right Cessation
- 1979-03-29 AT AT0235179A patent/AT376432B/de not_active IP Right Cessation
- 1979-03-29 FR FR7907863A patent/FR2421174A1/fr active Granted
- 1979-03-29 DK DK128679A patent/DK158225C/da not_active IP Right Cessation
- 1979-03-29 NO NO791049A patent/NO151321C/no unknown
- 1979-03-29 BE BE0/194281A patent/BE875174A/xx not_active IP Right Cessation
- 1979-03-29 SU SU792745704A patent/SU1140687A3/ru active
- 1979-03-30 PT PT69422A patent/PT69422A/pt unknown
- 1979-03-30 MX MX797848U patent/MX5862E/es unknown
- 1979-03-30 ES ES479134A patent/ES479134A1/es not_active Expired
- 1979-03-30 NL NLAANVRAGE7902514,A patent/NL183189C/xx not_active IP Right Cessation
- 1979-03-30 ZA ZA791516A patent/ZA791516B/xx unknown
- 1979-03-30 IT IT67674/79A patent/IT1119284B/it active
- 1979-03-30 GB GB7911155A patent/GB2017701B/en not_active Expired
- 1979-12-17 ES ES486991A patent/ES486991A1/es not_active Expired
- 1979-12-17 ES ES486992A patent/ES486992A1/es not_active Expired
- 1979-12-17 ES ES486990A patent/ES486990A1/es not_active Expired
-
1981
- 1981-09-08 SU SU813328599A patent/SU1232144A3/ru active
-
1982
- 1982-03-26 CH CH190082A patent/CH641350A5/de not_active IP Right Cessation
-
1987
- 1987-03-12 US US07/025,193 patent/US4824840A/en not_active Expired - Lifetime
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680105B2 (en) | 2001-01-29 | 2014-03-25 | Otsuka Pharmaceutical Co., Ltd. | Method of treating down's syndrome |
| US9387207B2 (en) | 2001-01-29 | 2016-07-12 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
| US8030312B2 (en) | 2001-01-29 | 2011-10-04 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
| US9089567B2 (en) | 2001-01-29 | 2015-07-28 | Otsuka Pharmaceutical Co., Ltd. | Method of treating cognitive impairments and schizophrenias |
| US8426423B2 (en) | 2001-01-29 | 2013-04-23 | Otsuka Pharmaceutical Co., Ltd. | Method of treating Attention Deficit Hyper-Activity Disorder |
| US9006248B2 (en) | 2001-01-29 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
| US8604041B2 (en) | 2001-01-29 | 2013-12-10 | Otsuka Pharmaceutical Co., Ltd. | Method of treating panic disorder |
| US8623874B2 (en) | 2001-01-29 | 2014-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of treating neurodegenerative diseases |
| US8722680B2 (en) | 2001-01-29 | 2014-05-13 | Otsuka Pharmaceutical Co., Ltd. | Method of treating neurodegenerative diseases |
| US8642600B2 (en) | 2001-01-29 | 2014-02-04 | Otsuka Pharmaceutical Co., Ltd. | Method of treating autism |
| US8580796B2 (en) | 2001-09-25 | 2013-11-12 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8703773B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8642760B2 (en) | 2001-09-25 | 2014-02-04 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8901303B2 (en) | 2001-09-25 | 2014-12-02 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8901130B2 (en) | 2001-09-25 | 2014-12-02 | Ostuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation |
| US8993761B2 (en) | 2001-09-25 | 2015-03-31 | Otsuka Pharamceutical Co. Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US7910589B2 (en) | 2001-09-25 | 2011-03-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8399469B2 (en) | 2001-09-25 | 2013-03-19 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US9359302B2 (en) | 2001-09-25 | 2016-06-07 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US8017615B2 (en) | 2001-09-25 | 2011-09-13 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| US10150735B2 (en) | 2001-09-25 | 2018-12-11 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2912105C2 (de) | Neue carbostyrilderivate, verfahren zu deren herstellung und diese enthaltende mittel | |
| US6750218B2 (en) | Nitrogen-containing heterocyclic compounds | |
| EP0584091B1 (de) | Benzopyranone, verfahren zu ihrer herstellung und verwendung | |
| DE69232336T2 (de) | Stickstoff enthaltende hydrocyclische verbindungen | |
| DE69611361T2 (de) | Chinazolin-derivate | |
| DE3888821T2 (de) | Tricyclische Verbindungen. | |
| DE2559509A1 (de) | Benzcyloamidderivate und verfahren zu ihrer herstellung sowie pharmazeutische mittel, worin sie enthalten sind | |
| DE2934747A1 (de) | Tetrazolylalkoxycarbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten | |
| DE2428858A1 (de) | 1,3-disubstituierte 2,4(1h,3h)chinazolin-derivate | |
| DE2345064A1 (de) | 2- oder 4-aminochinazolinderivate und pharmazeutische mittel | |
| DE3034237C2 (cg-RX-API-DMAC10.html) | ||
| DE2740588A1 (de) | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -chinolin-2-carbon- saeuren und deren derivate sowie pharmazeutische zubereitungen, die diese verbindungen enthalten | |
| DE3105330A1 (de) | "4-amino-6,7-dimethoxy-2-piperazinylchinazolin-derivate, ihre herstellung und ihre verwendung" | |
| DE3622036A1 (de) | Benzimidazolderivate | |
| DE69004702T2 (de) | Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese Derivate enhaltende Zusammensetzungen. | |
| DE3852332T2 (de) | 4-Thiochinazolin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellungen. | |
| DE2711719C2 (de) | 3,4-Dihydrocarbostyril-Derivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten | |
| DE2526983A1 (de) | Pyrido/1,2-a/pyrimidinon-derivate und verfahren zu deren herstellung | |
| DD157614A5 (de) | Verfahren zur herstellung von pyrimidyl-chinazolinen | |
| DE2847623C2 (de) | 4-Amino-2-(piperazin-1-yl oder homopiperazin-1-yl)-chinazolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE3874465T2 (de) | 1,2,3,4-tetrahydroisochonoline als antiarrhythmische mittel. | |
| DE2461670A1 (de) | 5,6-benzo-gamma-pyronderivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen | |
| DD293349A5 (de) | Verfahren zur herstellung neuer thiouracilderivate und ihrer saeureadditionssalze | |
| US4250177A (en) | Substituted 10-oxo-10H-pyridazino(6,1-b)quinazoline-2-carboxylic acids | |
| AT376435B (de) | Verfahren zum herstellen von neuen carbostyrilderivaten und von deren saeureadditionssalzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OAP | Request for examination filed | ||
| OD | Request for examination | ||
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 2953723 Format of ref document f/p: P |
|
| AH | Division in |
Ref country code: DE Ref document number: 2953723 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 2953723 |
|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| AH | Division in |
Ref country code: DE Ref document number: 2953723 Format of ref document f/p: P |
|
| AH | Division in |
Ref country code: DE Ref document number: 2953723 Format of ref document f/p: P |
|
| 8366 | Restricted maintained after opposition proceedings | ||
| 8305 | Restricted maintenance of patent after opposition | ||
| AH | Division in |
Ref country code: DE Ref document number: 2953723 Format of ref document f/p: P |
|
| D4 | Patent maintained restricted |